高コレステロール血症におけるインクリシランベースの治療戦略: VICTORION- 差異試験
Ulf Landmesser1, Ulrich Laufs2, Ulrike Schatz3
1Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité; Charité-Universitätsmedizin Berlin, German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany.
European heart journal
|August 30, 2025
まとめ
低密度脂質タンパク質コレステロール (LDL- C) の目標達成と低下をインクリシランが有意に改善した. この治療法では,最適化された脂質低下療法と比較して,筋肉関連の有害事象が少ないことが示されました.
科学分野:
- 心臓病科
- 薬理学について
- 臨床試験
背景:
- 低密度の脂質タンパク質コレステロール (LDL-C) は,動脈硬化性心血管疾患の主要な危険因子です.
- ヨーロッパの心臓学協会のガイドラインは,LDL-Cの目標を達成するために組み合わせ治療を推奨しています.
- 小型の干渉RNA (siRNA) であるインクリシランは,持続的なLDL- C減少のためにPCSK9mRNAを標的とする.
研究 の 目的:
- インクリシランと個別に最適化された脂質低下療法 (IOLLT) を受けた患者とプラセボとIOLLTを併用した患者の間で,90日目のLDL- C目標の達成度を評価する.
- 筋肉関連の有害事象 (MRAE) と平均LDL-C減少を二次目標として評価する.
主な方法:
- 4期,ダブルブラインド,プラセボ対照VICTORION- 差異試験
- 高/ 非常に高いCVリスクを有する成人は,インクリシランまたはプラセボに1対1でランダムに割り当てられました.
- ロスウスタチンのオープンタイトリングを含むIOLLTは,すべての被験者に投与されました.
主要な成果:
- インクリシランでLDL- Cの目標値の達成率が90日 (OR 12. 09, p< 0. 001) で高かった.
- インクリシランの平均LDL- C減少値は,基値から360日までの間で,インクリシランの - 59. 5% とioLLTの - 24. 3% (LSMTD - 35. 14%,p< 0. 001) であった.
- インクリシラン (11. 9%) とioLLT (19. 2%) (OR0. 57, p< 0. 001) で報告されたMRAEは少なかった.
結論:
- インクリシランベースの治療は,高コレステロール血症におけるLDL-C目標達成においてioLLTよりも優れている.
- インクリシランは早期に持続的なLDL- Cの減少をもたらし,安全性プロファイルが好ましい.
- この研究では,インクリシランの投与でMRAEが少なく,生活の質の指標が改善された.
関連する概念動画
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
247
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
247